Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer. Issue 5 (15th April 2019)

• Record Type: Journal Article
• Authors: Link, Theresa; Kuhlmann, Jan Dominik; Kobelt, Dennis; Herrmann, Pia; Vassileva, Yana D.; Kramer, Michael; Frank, Kerstin; Göckenjan, Maren; Wimberger, Pauline; Stein, Ulrike
• Is Part Of: Molecular oncology. Volume 13:Issue 5(2019)
• Page Start: 1268
• Page End: 1279
• Publication Date: 2019-04-15
• Subjects: blood‐based biomarker -- MACC1 -- ovarian cancer -- prognosis -- S100A4 -- survival; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1002/1878-0261.12484
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Metastasis‐associated in colon cancer 1 (MACC1) and S100 calcium‐binding protein A4 (S100A4) are prominent inducers of tumor progression and metastasis. For the first time, we systematically tracked circulating serum levels of MACC1 and S100A4 transcripts in the course of surgery and chemotherapy and analyzed their clinical relevance for ovarian cancer. MACC1 and S100A4 transcripts were quantified in a total of 318 serum samples from 79 ovarian cancer patients by RT‐qPCR and digital droplet PCR, respectively. MACC1 and S100A4 transcripts were significantly elevated in serum of ovarian cancer patients, compared to healthy controls ( P = 0.024; P < 0.001). At primary diagnosis, high levels of MACC1 or S100A4 correlated with advanced FIGO stage ( P = 0.042; P = 0.008), predicted suboptimal debulking surgery and indicated shorter progression‐free survival (PFS; P = 0.003; P = 0.001) and overall survival (OS; P = 0.001; P = 0.002). This is the first study in ovarian cancer to propose circulating MACC1 and S100A4 transcripts as potential liquid biopsy markers. Abstract : We analyzed the clinical relevance of circulating MACC1 and S100A4 transcripts in ovarian cancer patients. We report that high serum levels of both transcripts at primary diagnosis (but not in the course of surgery and chemotherapy) are associated with advanced disease and indicate poor survival. Our results suggest blood‐based MACC1 and S100A4 transcripts as innovative liquid biopsy markers for ovarian cancer.